The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm

• Status: Unknown status
• Trial end date: 2018-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study was to to evaluate the effect of sarpogrelate, a selective serotonin receptor antagonist, and high dose statin on the reduction of coronary spasm in the patients with variant angina.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Atorvastatin; Atorvastatin Calcium; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Sarpogrelate

Criteria

Inclusion Criteria:

• Clinical history of chest pain compatible with variant angina; morning chest pain aggravated by cold exposure.

• Angiographically proven coronary spasm; TIMI flow < 3 by spontaneous coronary spasm or intracoronary ergonovine spasm provocation test.

Exclusion Criteria:

• Cardiac arrest by coronary spasm

• Left main coronary spasm

• Significant fixed coronary artery stenosis; Diameter stenosis > 70% in the major epicardial artery by coronary angiography

• Left ventricular ejection fraction < 30%

• Coagulation disorders or bleeding tendency (Platelet count < 50k, PT INR > 2.0)

• Significant liver disease (AST or ALT > 100 U/ml)

• Renal failure (S-Cr > 2.0 mg/dl)

• hypersensitivity for statin

• Pregnancy